A discussion between Dr. Peter Anglin and Dr. Matthew S. Davids (Fall 2021)

In this final episode, Dr. Anglin and Dr. Davids discuss recent developments and evidence that is likely to frame the future of CLL management. They review emerging data from trials assessing efficacy and safety of various novel agents and combinations in different patient populations. The experts also discuss promising biomarkers that could assist in therapeutic decision-making and address sequencing-related questions, including the role of MRD monitoring in routine practice.

Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON

Matthew S. Davids, MD, MMSc Hematologist/Oncologist Associate Professor of Medicine, Harvard Medical School Director, Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel A. Pollyea and Dr. Michelle Geddes (Fall 2021)

In this final episode of the AML podcast series, Dr. Pollyea and Dr. Geddes share their experience with using antifungal prophylaxis with novel AML treatment approaches. They review the risk factors and discuss caveats regarding the impact of antifungals on venetoclax dosing regimens, and, most importantly, on the efficacy in treating the disease.

Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine

Michelle Geddes, MD, FRCPC Clinical Associate Professor, Division of Hematology, University of Calgary

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Carolyn Owen (Fall 2021)

In this episode, Dr. Anglin and Dr. Owen elaborate on discussions with patients that take place once a decision to initiate a particular treatment is made. They share their insights on how to reassure a patient while explaining potential side effects and monitoring requirements. Differences in conversations when a patient is treated with a BTK inhibitor vs venetoclax-based regimens are highlighted as well as the challenges associated with patient adherence.

Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON

Carolyn Owen, MD, MDres(UK), FRCPC Hematologist, Tom Baker Cancer Centre Associate Professor, Division of Hematology & Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary Local Principal Investigator, Tom Baker Cancer Centre

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel A. Pollyea and Dr. Julie Bergeron (Fall 2021)

In this third episode of the AML podcast series, Dr. Daniel Pollyea and Dr. Julie Bergeron share some practical tips and insights regarding the management of neutropenia in patients treated with venetoclax + azacitidine. They highlight the importance of bone marrow assessments in guiding therapeutic decisions throughout treatment cycles.

Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine

Julie Bergeron, MD, FRCPC Hematologist at CEMTL Installation Maisonneuve-Rosemont Associate Professor, Université de Montréal Lead, Acute Leukemia Sub-Section of Clinical Research Unit at CEMTL Head of Service, Hematology Laboratory Optilab Montreal-CHUM

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Versha Banerji (Fall 2021)

In this third episode, Dr. Anglin and Dr. Banerji focus on CLL treatment initiation from a patient’s perspective. They share their insights on how to engage a patient in the decision-making process and how to present different options to the patient in an informative and unbiased way. They also discuss how patients’ reactions to the specific aspect of treatments guide their consultation and lead to the ultimate treatment-related decision.

Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON

Versha Banerji MD, FRCPC Clinician Scientist and Associate Professor, Faculty of Medicine, Departments of Internal Medicine, Biochemistry & Medical Genetics, Max Rady School of Medicine, Rady Faculty of Health Sciences, University of Manitoba CLL clinic and research Co-Lead Hematologist, CancerCare Manitoba Senior Scientist, CancerCare Manitoba Research Institute Adjunct Professor, Department of Biology, University of Winnipeg

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel A. Pollyea and Dr. Brian Leber (Fall 2021)

Dr. Daniel Pollyea and Dr. Brian Leber share their experience with the venetoclax plus azacitidine combination. Through a patient case, Dr. Leber brings up important considerations for patient selection and treatment initiation, focusing on the importance of proper management of early treatment-related adverse events, which, as illustrated by this case, could be quite severe.  Dr. Pollyea explains how to assess treatment response, adjust further therapeutic approaches, including transplant, and counsel patients accordingly.

Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine. 

Brian Leber, MD, BSc, MDCM, FRCPC Professor of Medicine (Hematology) McMaster University Attending Physician and Hematologist Head, Leukemia Group Co-Director, Cellular Therapy Programme (formerly Stem Cell Transplant Programme) Director, Molecular Hematology Laboratory Juravinski Hospital and Cancer Centre, Hamilton Health Sciences

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Othman Al-Sawaf (Fall 2021)

Dr. Peter Anglin and Dr. Othman Al-Sawaf discuss therapeutic options for newly diagnosed CLL patients – from risk stratification and patient preferences to treatment duration and sequencing considerations.  They examine data from clinical trials, review toxicity profiles of various approaches, and contrast the options of being on continuous vs fixed duration therapy from the patient’s and physician’s perspectives.

Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON

Othman AI-Sawaf, MD Hematologist/Oncologist University Hospital of Cologne, Germany Study physician, German CLL Study Group (GCLLSG)

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Daniel Pollyea and Dr. Andre Schuh (Fall 2021)

In this episode, Dr. Daniel Pollyea and Dr. Andre Schuh share their experience with using novel therapies in managing AML patients ineligible for intensive chemotherapy. They provide their take on frailty in the context of recent additions to the AML treatment armamentarium and further discuss factors that impact therapeutic decision-making, from patient and disease characteristics to the access and reimbursement landscape.

Daniel A. Pollyea, MD, MS Associate Professor of Medicine Clinical Director of Leukemia Services Robert H. Allen MD Chair in Hematology Research Division of Hematology University of Colorado School of Medicine

Andre Schuh,BSc, MD, FRCPC Staff Physician, University Health Network/Princess Margaret Cancer Centre Toronto, ON

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.

A discussion between Dr. Peter Anglin and Dr. Anthony Mato (Fall 2021)

In this episode, Dr. Peter Anglin and Dr. Anthony Mato discuss therapeutic decision-making in the evolving CLL treatment landscape and the diminishing role of chemoimmunotherapy. They provide their take on selecting between continuous therapy with BTK inhibitors and finite treatment duration with venetoclax-based regimens and they elaborate on various factors that come into play when choosing first and subsequent line therapy.

Peter Anglin, MD, FRCPC, MBA Hematologist/Oncologist Physician Lead, Stronach Regional Cancer Centre Newmarket, ON

Anthony R. Mato, MD, MSCE Associate Member, Memorial Sloan Kettering Cancer Director, Chronic Lymphocytic Leukemia (CLL) Program at MSKCC New York, USA

This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.